Group 1 - The National Medical Products Administration (NMPA) held a national drug regulation work conference and "Qingyuan" action promotion meeting in Zhengzhou [1] - The meeting emphasized the need to strengthen risk assessment and firmly combat illegal and non-compliant activities [1] - The meeting also highlighted the continuation of information traceability efforts and the enhancement of comprehensive management across all varieties and the entire supply chain [1] - Additionally, the meeting called for the improvement of institutional standards to further guide and regulate drug business activities [1]

Core Viewpoint - The Urumqi Market Supervision Administration is intensifying efforts to regulate the pharmaceutical distribution sector through a "Clean Source" initiative aimed at addressing prominent issues in drug sales and ensuring drug quality safety [1][3][4] Group 1: Regulatory Actions - The administration has mobilized 127 pharmaceutical companies to adhere to principles of "strict prevention at the source, strict management during the process, and strict risk control" [3] - Key focuses include combating illegal drug sales, counterfeit drugs, and violations in online drug sales [3] - Specific measures include enhanced online inspections, strict checks on illegal procurement channels, and increased oversight of high-risk drugs [3] Group 2: Compliance and Training - The administration emphasizes the importance of compliance by requiring pharmaceutical companies to implement full product traceability and rectify identified issues [3][4] - Future plans include ongoing training for pharmacy staff to ensure comprehensive understanding of regulations, thereby safeguarding public health [4]